Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Erben

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Seminars in Hematology|February 13, 2007
Resistance to targeted therapy in chronic myelogenous leukemiaAndreas Hochhaus, Philipp Erben, Thomas Ernst, et al.
World Journal of Urology|July 15, 2025
Unicorns transforming the practice of urology: value creation and allocation in the digital agePhilipp Erben, Severin Rodler, Amin T Turki, et al.
Der Urologe. Ausg. A|November 26, 2020
[Molecular subtypes of urothelial carcinoma of the bladder-background and clinical relevance]Philipp Erben, Christoph Becker, Igor Tsaur, et al.
Plos One|June 20, 2025
Proliferation and regeneration of the healthy human urothelium: A multi-scale simulation approach with 16 hypotheses of cell differentiationFabian Siegel, Angelo Torelli, Minca Mattis, et al.
Annals of Hematology|October 6, 2010
The role of zinc protoporphyrin measurement in the differentiation between primary myelofibrosis and essential thrombocythaemiaGeorgia Metzgeroth, Eva-Maria Kanders, Philipp Erben, et al.
Clinical Chemistry and Laboratory Medicine|February 29, 2008
Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemiaThomas Ernst, Jana Hoffmann, Philipp Erben, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Cause and management of therapy resistanceAndreas Hochhaus, Thomas Schenk, Philipp Erben, et al.
Anticancer Research|August 28, 2004
Acoustic energy: a new transfection method for cancer of the prostate, cancer of the bladder and benign kidney cellsMaurice Stephan Michel, Philipp Erben, Lutz Trojan, et al.
Advances in Urology|August 13, 2014
IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking StatusThomas S Worst, Verena Reiner, Ute Gabriel, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2018
FOXM1 predicts disease progression in non-muscle invasive bladder cancerSebastien Rinaldetti, Ralph Wirtz, Thomas Stefan Worst, et al.
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Seminars in Hematology|February 13, 2007
Resistance to targeted therapy in chronic myelogenous leukemiaAndreas Hochhaus, Philipp Erben, Thomas Ernst, et al.
World Journal of Urology|July 15, 2025
Unicorns transforming the practice of urology: value creation and allocation in the digital agePhilipp Erben, Severin Rodler, Amin T Turki, et al.
Der Urologe. Ausg. A|November 26, 2020
[Molecular subtypes of urothelial carcinoma of the bladder-background and clinical relevance]Philipp Erben, Christoph Becker, Igor Tsaur, et al.
Plos One|June 20, 2025
Proliferation and regeneration of the healthy human urothelium: A multi-scale simulation approach with 16 hypotheses of cell differentiationFabian Siegel, Angelo Torelli, Minca Mattis, et al.
Annals of Hematology|October 6, 2010
The role of zinc protoporphyrin measurement in the differentiation between primary myelofibrosis and essential thrombocythaemiaGeorgia Metzgeroth, Eva-Maria Kanders, Philipp Erben, et al.
Clinical Chemistry and Laboratory Medicine|February 29, 2008
Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemiaThomas Ernst, Jana Hoffmann, Philipp Erben, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Cause and management of therapy resistanceAndreas Hochhaus, Thomas Schenk, Philipp Erben, et al.
Anticancer Research|August 28, 2004
Acoustic energy: a new transfection method for cancer of the prostate, cancer of the bladder and benign kidney cellsMaurice Stephan Michel, Philipp Erben, Lutz Trojan, et al.
Advances in Urology|August 13, 2014
IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking StatusThomas S Worst, Verena Reiner, Ute Gabriel, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2018
FOXM1 predicts disease progression in non-muscle invasive bladder cancerSebastien Rinaldetti, Ralph Wirtz, Thomas Stefan Worst, et al.
Pageof 13